HUTCHMED Advances HMPL-760 to Registrational Phase III for DLBCL in China

summarizeSummary

HUTCHMED has initiated a registrational Phase III clinical trial for its investigational drug HMPL-760 in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China, a significant step towards potential market approval.

check_boxKey Events

• Phase III Trial Initiation

  HUTCHMED has initiated a registrational Phase III clinical trial for HMPL-760 in combination with R-GemOx for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in China, with the first patient dosed on March 20, 2026.

• Targeting DLBCL

  DLBCL is the most common aggressive non-Hodgkin lymphoma in China, with approximately 81,000 new cases estimated in 2022, representing a significant market opportunity for HMPL-760.

• Encouraging Prior Results

  The decision to advance to Phase III follows encouraging improvements in objective response rate, complete response rate, progression-free survival, and overall survival observed in a previous Phase II study.

• Global Rights Retained

  HUTCHMED retains all worldwide rights to HMPL-760, maximizing potential future revenue streams from the drug.

auto_awesomeAnalysis

HUTCHMED's initiation of a registrational Phase III trial for HMPL-760 marks a significant advancement in its drug pipeline. This trial targets relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a prevalent and aggressive cancer in China, representing a substantial market opportunity. The move to Phase III is supported by encouraging results from a prior Phase II study, suggesting HMPL-760, a third-generation BTK inhibitor, has promising efficacy and a manageable safety profile. Retaining global rights to the drug positions HUTCHMED to fully capitalize on its potential success, which could significantly impact the company's long-term growth trajectory and address a critical unmet medical need.